On the other hand, targeting glutamine metabolism with broad glutamine antagonists or GLS inhibitors are currently available and they have demonstrated preclinical efficacy in several cancer types.8,11 The pleiotropic effect of a glutamine antagonist provides a possible opportunity to disrupt the glutamine metabolism addiction observed of malignant growth. This evidence concerns the gene GLS and cancer.